Drug intelligence / Profile preview

miR-23b

Development stage: Preclinical
Lead developer: Mayo Clinic
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

miR-23b is a microRNA that functions as a tumor suppressor by post-transcriptionally regulating genes involved in cell motility and survival. In the context of glioblastoma, miR-23b is frequently down-regulated, and its restoration has been shown to inhibit glioma cell migration and invasion. This effect is primarily mediated through the direct targeting of the 3' untranslated region (UTR) of the Pyk2 (PTK2B) mRNA, a non-receptor tyrosine kinase critical for cytoskeletal reorganization. Beyond its role in oncology, miR-23b is also involved in modulating inflammatory pathways and has been investigated for its potential in treating autoimmune conditions by targeting pathways such as NF-κB.

Other names: microRNA-23bmicroRNA23bmicroRNA 23bmiRNA-23bmiRNA23bmiRNA 23b

Targets

CCNG1 (Cyclin G1 mRNA)PTK2B

Beyond the preview

Go deeper on miR-23b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-23b.